Undisclosed PI3Kα pan-mutant inhibitor / OnKure - LARVOL DELTA

Next-Generation PI3KαPAN Mutant Selective Program (GlobeNewswire) - "OnKure expects to announce its next-generation PI3Kα pan-mutant inhibitor candidate for HR+ metastatic breast cancer in March 2026....OnKure believes its differentiated portfolio of PI3Kα inhibitors has significant potential to address a large and underserved patient population. The Company expects to provide additional details on its PI3Kα pan‑mutant program in 2026."

Pipeline update • Hormone Receptor Positive Breast Cancer

Next-Generation PI3KαPAN Mutant Selective Program (GlobeNewswire) - "The Company is evaluating a series of PI3Kα pan-mutant inhibitor development candidates shown preclinically to have an overall selectivity profile, combinability, and pharmaceutical attributes that the Company believes will produce best-in-class pan-mutant PI3Kα inhibitors. The Company plans to announce additional details in the first quarter of 2026."

Preclinical • Solid Tumor

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - "...Upcoming Anticipated Milestones:...Pan-mutant Program - OnKure believes a PI3Kα 'pan-mutant' inhibitor will need to demonstrate approximately 10-fold selectivity against each of the most common mutations (PI3KαH1047X, PI3KαE542K, and PI3KαE545K) over wild type. OnKure expects to announce its pan-mutant development candidate in the second quarter of 2025."

Pipeline update • Oncology